Stomach cancer — also called gastric cancer — is among the more challenging cancer types from a life insurance underwriting perspective. Diagnosis often occurs at later stages, survival rates vary significantly by stage, and the underwriting timeline is typically longer than for more favorable cancers. That said, survivors diagnosed at early stages with successful surgical treatment and sustained remission have meaningful options. This guide explains exactly what insurers look at, what to expect by stage, and which policy types are realistically available at different points in your recovery.

Why Stomach Cancer Underwriting Is Complex

Stomach cancer presents particular underwriting challenges for several reasons. First, approximately 70% of stomach cancer diagnoses occur at Stage III or IV — stages where survival rates are significantly lower and underwriting timelines are much longer. Second, there is no reliable early-detection screening widely used in the United States (unlike colonoscopy for colorectal cancer or mammography for breast cancer), which means early-stage diagnoses are less common. Third, the location of the tumor within the stomach — proximal (near the esophagus), mid-body, or distal (near the small intestine) — affects both prognosis and underwriting, with proximal tumors generally having a less favorable outlook. These factors combine to make stomach cancer one of the cancer types where insurer-specific knowledge and broker expertise matter most.

Key Factors Underwriters Evaluate for Stomach Cancer

Stage at Diagnosis

The TNM staging system is what underwriters use to assess stomach cancer risk. Stage is the most important single factor:

  • Stage IA (T1N0M0): Tumor limited to the inner layers of the stomach wall, no lymph node involvement, no distant spread. The most favorable underwriting scenario for stomach cancer. Some carriers will consider applications 2–3 years after treatment with clean follow-up. Five-year survival rates for Stage IA are generally estimated at 70% or above.
  • Stage IB–IIA (T2–T3, N0–N1, M0): Tumor growing into the muscle layer or beyond, with limited or no lymph node involvement. Standard coverage typically requires 5+ years of sustained clean remission. Table ratings are expected even after the waiting period.
  • Stage IIB–IIIC (T3–T4, N1–N3, M0): Tumor extending through the stomach wall with regional lymph node involvement. Very limited standard underwriting options. Simplified issue may become available after 5–7 years of documented remission at favorable carriers. Guaranteed issue is the most accessible near-term option for most of this group.
  • Stage IV (M1): Distant metastasis present. Standard and simplified issue policies are generally not available. Guaranteed issue and final expense coverage are typically the only accessible options. After 10+ years of documented complete remission — a relatively uncommon outcome at Stage IV — some carriers may reconsider on a case-by-case basis.

Tumor Location

Where the tumor originated within the stomach affects prognosis and underwriting. Distal (antral) tumors — in the lower part of the stomach near the small intestine — have historically had somewhat more favorable outcomes than proximal tumors at the gastroesophageal junction. Proximal gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma are increasingly common, particularly in the U.S., and are often treated and underwritten similarly to esophageal cancer. Underwriters will ask about tumor location from your pathology or operative report, so knowing this detail before applying is important.

Lymph Node Status

Lymph node involvement (the "N" in TNM staging) is one of the most prognostically important factors for stomach cancer, and underwriters weight it heavily. The number of lymph nodes examined and the number found to contain cancer cells matters. N0 (no lymph node involvement) is a strong favorable signal. N1 (1–2 positive nodes), N2 (3–6 positive nodes), and N3 (7+ positive nodes) each represent progressively higher risk and longer required waiting periods before standard coverage becomes available. If your surgery included an adequate lymph node dissection (D2 dissection, with 15+ nodes examined), document this — it provides important prognostic information.

Surgical Margins

Whether surgical resection achieved clear margins — meaning no cancer cells at the edges of the removed tissue — is an important underwriting factor. An R0 resection (microscopically clear margins) is the most favorable surgical outcome and a positive signal for underwriters. R1 (microscopic residual disease) or R2 (macroscopic residual disease) resections indicate incomplete removal and significantly affect underwriting outcomes.

Treatment Received

The treatment approach reflects the extent of your disease:

  • Endoscopic resection (EMR/ESD): Used for very early-stage (T1a) tumors limited to the mucosal layer. The most favorable treatment history for underwriting purposes. Clean endoscopic surveillance records are essential.
  • Subtotal or total gastrectomy with D2 lymphadenectomy: Standard curative-intent surgery for resectable stomach cancer. Negative margins and negative nodes are key favorable signals.
  • Perioperative chemotherapy (FLOT, FOLFOX): Increasingly standard for resectable Stage II–III disease. Indicates more advanced disease than surgery alone but is not itself a negative underwriting signal if combined with favorable pathologic response.
  • Chemoradiation (adjuvant): Sometimes used after surgery. Indicates higher-risk disease.
  • Palliative chemotherapy or targeted therapy: Used for Stage IV or unresectable disease. Indicates the cancer was not amenable to curative treatment. Standard underwriting is generally not available in this situation.

Pathologic Response to Neoadjuvant Chemotherapy

For patients who received chemotherapy before surgery (neoadjuvant treatment), the degree of pathologic response — how much the tumor shrank or was eliminated by treatment — is an important prognostic factor. A complete pathologic response (no viable tumor cells in the surgical specimen) is a strongly favorable signal. Underwriters at sophisticated carriers are aware of this distinction, and having your pathology report documenting the response grade is valuable.

Remission Duration and Surveillance Compliance

Consistent, documented follow-up is essential for stomach cancer underwriting. Surveillance typically includes endoscopy, CT imaging, and clinical examination at regular intervals — often every 3–6 months for the first 2 years, then annually. Clean surveillance results at every visit, and consistent attendance at all follow-up appointments, are the strongest positive signals available to stomach cancer survivors seeking life insurance. Any recurrence, even if subsequently treated successfully, significantly extends required waiting periods.

Approximate Waiting Periods and Coverage Outlook

These are general industry ranges. Individual carrier guidelines vary considerably. An impaired-risk specialist broker will have knowledge of which specific carriers are most favorable for stomach cancer at each stage.

Stage IA, Endoscopic Resection or Gastrectomy, R0, N0, Clean Surveillance

The most favorable stomach cancer underwriting scenario. Some carriers will consider applications 2–3 years after treatment. Table ratings are typical in early years. After 5+ years of consistently clean surveillance, standard or near-standard rates may be available at favorable carriers. This profile represents a small subset of stomach cancer survivors but has meaningfully better underwriting prospects than most.

Stage IB–IIA, Gastrectomy, R0, Limited Lymph Node Involvement

Standard coverage is typically available after 5+ years of clean follow-up. Table ratings are expected even at that point. Simplified issue is a practical option during the first 3–5 years post-treatment. An independent broker can identify carriers with more favorable guidelines for this profile.

Stage IIB–IIIC, Regional Lymph Node Involvement

Standard coverage requires extended clean remission — typically 7–10 years at most carriers. Simplified issue may become available after 5+ years of documented complete remission. Guaranteed issue and group coverage are the most accessible options in the earlier years after treatment.

Stage IV or Unresectable Disease

Standard and simplified issue coverage are generally not available in the near term. Guaranteed issue and final expense policies are the realistic options. Employer group coverage, if available, provides meaningful protection without individual underwriting.

Policy Types Available to Stomach Cancer Survivors

Standard Term or Whole Life (Fully Underwritten)

Available to survivors with favorable profiles — typically early-stage, R0 resection, negative or limited lymph node involvement, and sustained remission of 3–5+ years. Always work with an independent broker who specializes in impaired risk. Carrier variation for stomach cancer is significant, and applying to the wrong carrier can result in a decline that creates a Medical Information Bureau (MIB) record affecting future applications.

Simplified Issue

No medical exam, streamlined health questions. Coverage amounts can reach $300,000–$500,000 at some carriers. A practical option for stomach cancer survivors whose profile would result in a decline or very high table rating under full underwriting. Premiums are higher than standard but coverage amounts are meaningful for income replacement and debt coverage.

Graded Benefit

Full death benefit after a 2–3 year waiting period; return of premium plus interest if death occurs during the graded period. No medical exam required. Useful during the period when standard or simplified issue is not accessible. Coverage typically in the $50,000–$150,000 range.

Guaranteed Issue

No health questions, guaranteed acceptance within eligible age ranges (typically 45–85). Coverage limited to approximately $5,000–$25,000 with a 2-year graded benefit period. High premiums relative to benefit amount. Best suited for final expense coverage when no other individual option is accessible. Not suitable as primary income replacement coverage.

Group Life Insurance

Employer-sponsored group coverage provides meaningful protection without individual medical underwriting. Particularly valuable in the years immediately following stomach cancer treatment, when individual underwriting is most challenging. Maximize this coverage if your employer offers it. Some professional associations also offer group term coverage that may be accessible.

H. pylori and Its Relevance to Underwriting

Helicobacter pylori (H. pylori) infection is the most significant risk factor for non-cardia stomach cancer, and eradication of H. pylori is often part of post-treatment management. If H. pylori was identified and treated, document the eradication confirmation — a negative H. pylori test following treatment is a positive clinical signal. Underwriters at some carriers are aware of H. pylori's role in gastric cancer, and documented eradication can be a favorable factor in your underwriting narrative.

Practical Steps Before Applying

  1. Obtain complete records from your oncologist and gastroenterologist. Pathology reports (including TNM staging, lymph node count, margin status, and grade), operative notes, chemotherapy treatment summaries, and all surveillance endoscopy and imaging records.
  2. Know your exact stage, lymph node status, and margin status. "Stage II stomach cancer" is not specific enough for underwriting purposes. Know your T, N, and M categories, how many nodes were examined and how many were positive, and whether margins were R0, R1, or R2.
  3. Document your surveillance compliance. Every clean endoscopy and CT scan is a positive underwriting signal. Bring documentation of all scheduled follow-up visits.
  4. Work with an independent broker specializing in impaired risk. Stomach cancer underwriting is highly carrier-specific. A specialist knows which carriers are most favorable for your specific stage and profile. The wrong first application can create a MIB record that complicates all future applications.
  5. Maximize group coverage in the meantime. While working toward qualification for individual coverage, maximize employer group life insurance. This provides meaningful income protection for your family during the period when individual underwriting is most challenging.
  6. Re-shop as your remission time increases. Stomach cancer underwriting outcomes improve meaningfully with time. A profile that results in a decline at 2 years post-treatment may be insurable at standard or near-standard rates at 5 or 7 years. Review your options annually.

How Much Coverage Do You Need?

Your coverage need is based on your financial situation — income, debts, dependents, and future obligations — not your health history. Use our Life Insurance Calculator to estimate the right amount before approaching carriers. Having a clear coverage target helps ensure you're pursuing the right solution rather than simply taking what's easiest to obtain.

Other Cancer Guides in This Series

For more detailed underwriting information on other cancer types, see our complete series:

Bottom Line

Stomach cancer survivors face a more complex underwriting path than survivors of many other cancer types — but the path is not closed. Early-stage survivors with R0 resections, negative or limited lymph node involvement, and sustained clean surveillance have meaningful options, including standard coverage after sufficient remission time. Later-stage survivors have options through simplified issue, graded benefit, and guaranteed issue policies that provide real protection for their families while working toward eligibility for standard coverage. In all cases, an independent broker with impaired-risk expertise and knowledge of carrier-specific guidelines is the most important resource in navigating this process successfully.

This content is for informational purposes only and does not constitute insurance, financial, or legal advice. Insurance options vary by carrier, state, and individual health history. Always consult a licensed insurance professional before making coverage decisions.